Oragenics Inc (OGEN)

$1.15 -0.04 (-3.36%)
Market Cap 4.75M
Revenue (ttm) 0.00
Net Income (ttm) -10.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 73,200
Avg Vol 594,964
Day's Range N/A - N/A
Shares Out 4.13M
Stochastic %K 38%
Beta 0.65
Analysts Strong Buy
Price Target $2.00

Company Profile

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplif...

Industry: Biotechnology
Sector: Healthcare
Phone: 813 286 7900
Fax: 813 286 7900
Address:
1990 Main Street, Suite 750, Sarasota, United States
RocketQueen
RocketQueen Aug. 17 at 3:54 PM
$OGEN follow the price target which is .00001
0 · Reply
smoketuna
smoketuna Aug. 17 at 3:54 PM
$OGEN 85% with 🎯 TunaSignal.ai score! while price $1.15 - Catch the Big Movers Before They Break Out - Powered by AI
0 · Reply
ChloeHobbs
ChloeHobbs Aug. 17 at 1:37 PM
$OGEN Follow the price target.
1 · Reply
RocketQueen
RocketQueen Aug. 17 at 3:25 AM
$OGEN it's not clear to me how an entity like Oragenics can be allowed to stay incorporated for so long when it is clear they have produced no products, services or ever delivered on money raised from investors. It should be apparent to the board that it's time to shut this (now obvious) scam down.
0 · Reply
Jimmymalik123
Jimmymalik123 Aug. 16 at 9:31 PM
$OGEN it’s crazy how only recently they did a reverse stock split and it’s already gone back to $1 jeez how bad is this stock! Even if it rises by 500% here… it’s not even going back to the reverse split point … which I swear is a joke!
0 · Reply
RocketQueen
RocketQueen Aug. 16 at 8:54 PM
$OGEN under a 100k volume last Friday. This is truly garbage. They are not fooling anyone anymore.
1 · Reply
Rage_monger
Rage_monger Aug. 16 at 1:09 AM
$OGEN
0 · Reply
Rage_monger
Rage_monger Aug. 16 at 1:08 AM
$OGEN continued…
0 · Reply
NMax
NMax Aug. 15 at 11:22 PM
$OGEN if you haven't figured it out already, this is a multi-government operation. But good luck with that.
1 · Reply
RocketQueen
RocketQueen Aug. 15 at 8:58 PM
$OGEN is just a scam that's going nowhere. They still list 4 employees on their stock information. LOL At this point, it's only Janet running the bio-tech Ponzi scam with support from a criminal and greedy board. Less than a week ago, the market cap was only 2x her salary and retail thinks they can make a profit off a sinking company.
0 · Reply
Latest News on OGEN
Oragenics Q2 2025 Shareholder Update

Aug 11, 2025, 8:45 AM EDT - 6 days ago

Oragenics Q2 2025 Shareholder Update

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Jul 16, 2025, 8:39 AM EDT - 4 weeks ago

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Oragenics Completes Approximately $16.5 Million Offering

Jul 2, 2025, 4:15 PM EDT - 6 weeks ago

Oragenics Completes Approximately $16.5 Million Offering

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Jul 1, 2025, 8:31 AM EDT - 6 weeks ago

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

May 13, 2025, 8:30 AM EDT - 3 months ago

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

May 12, 2025, 8:30 AM EDT - 3 months ago

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Apr 7, 2025, 4:30 PM EDT - 4 months ago

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Mar 27, 2025, 8:30 AM EDT - 5 months ago

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Mar 18, 2025, 5:33 PM EDT - 5 months ago

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Mar 6, 2025, 9:30 AM EST - 5 months ago

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Feb 25, 2025, 8:30 AM EST - 6 months ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Feb 11, 2025, 8:30 AM EST - 6 months ago

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Feb 5, 2025, 8:15 AM EST - 6 months ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Jan 21, 2025, 8:15 AM EST - 7 months ago

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Dec 16, 2024, 8:09 AM EST - 8 months ago

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oct 18, 2024, 8:30 AM EDT - 10 months ago

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oct 9, 2024, 7:30 AM EDT - 11 months ago

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oct 8, 2024, 8:45 AM EDT - 11 months ago

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. Announces Closing of Public Offering

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Announces Closing of Public Offering

Oragenics, Inc. Announces Pricing of Public Offering

Sep 4, 2024, 8:36 AM EDT - 1 year ago

Oragenics, Inc. Announces Pricing of Public Offering

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Aug 21, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Aug 16, 2024, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Aug 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Oragenics, Inc. Announces Proposed Public Offering

Jun 24, 2024, 6:43 PM EDT - 1 year ago

Oragenics, Inc. Announces Proposed Public Offering

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

May 22, 2024, 8:00 AM EDT - 1 year ago

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

May 17, 2024, 8:00 AM EDT - 1 year ago

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Apr 19, 2024, 5:50 PM EDT - 1 year ago

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Oragenics, Inc. Files 10K and Provides Company Update

Apr 1, 2024, 9:05 AM EDT - 1 year ago

Oragenics, Inc. Files 10K and Provides Company Update

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Mar 18, 2024, 7:00 AM EDT - 1 year ago

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Mar 5, 2024, 7:45 AM EST - 1 year ago

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Closing of Public Offering

Mar 1, 2024, 4:04 PM EST - 1 year ago

Oragenics Announces Closing of Public Offering

Oragenics Announces Pricing of Public Offering

Feb 27, 2024, 9:25 PM EST - 1 year ago

Oragenics Announces Pricing of Public Offering

Oragenics Announces Proposed Public Offering

Feb 27, 2024, 4:33 PM EST - 1 year ago

Oragenics Announces Proposed Public Offering

Oragenics, Inc. Announces Leadership Transition

Feb 12, 2024, 4:41 PM EST - 1 year ago

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Feb 7, 2024, 8:00 AM EST - 1 year ago

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Feb 5, 2024, 8:00 AM EST - 1 year ago

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Oragenics Announces Termination of At-The-Market Offering Program

Jan 23, 2024, 5:34 PM EST - 1 year ago

Oragenics Announces Termination of At-The-Market Offering Program

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

Jan 2, 2024, 7:30 AM EST - 1 year ago

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

Oragenics Issues Update to Shareholders

Nov 2, 2023, 7:00 AM EDT - 1 year ago

Oragenics Issues Update to Shareholders

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

Oct 18, 2023, 8:30 AM EDT - 1 year ago

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Oct 18, 2023, 8:30 AM EDT - 1 year ago

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Oct 5, 2023, 6:30 AM EDT - 2 years ago

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

Sep 29, 2023, 4:00 PM EDT - 2 years ago

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

Oragenics, Inc. Announces Private Placement

Aug 7, 2023, 8:30 AM EDT - 2 years ago

Oragenics, Inc. Announces Private Placement

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

Jun 5, 2023, 4:18 PM EDT - 2 years ago

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

Oragenics to Participate in the World Vaccine Congress Washington

Mar 29, 2023, 11:45 AM EDT - 2 years ago

Oragenics to Participate in the World Vaccine Congress Washington

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

Mar 14, 2023, 8:30 AM EDT - 2 years ago

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

RocketQueen
RocketQueen Aug. 17 at 3:54 PM
$OGEN follow the price target which is .00001
0 · Reply
smoketuna
smoketuna Aug. 17 at 3:54 PM
$OGEN 85% with 🎯 TunaSignal.ai score! while price $1.15 - Catch the Big Movers Before They Break Out - Powered by AI
0 · Reply
ChloeHobbs
ChloeHobbs Aug. 17 at 1:37 PM
$OGEN Follow the price target.
1 · Reply
RocketQueen
RocketQueen Aug. 17 at 3:25 AM
$OGEN it's not clear to me how an entity like Oragenics can be allowed to stay incorporated for so long when it is clear they have produced no products, services or ever delivered on money raised from investors. It should be apparent to the board that it's time to shut this (now obvious) scam down.
0 · Reply
Jimmymalik123
Jimmymalik123 Aug. 16 at 9:31 PM
$OGEN it’s crazy how only recently they did a reverse stock split and it’s already gone back to $1 jeez how bad is this stock! Even if it rises by 500% here… it’s not even going back to the reverse split point … which I swear is a joke!
0 · Reply
RocketQueen
RocketQueen Aug. 16 at 8:54 PM
$OGEN under a 100k volume last Friday. This is truly garbage. They are not fooling anyone anymore.
1 · Reply
Rage_monger
Rage_monger Aug. 16 at 1:09 AM
$OGEN
0 · Reply
Rage_monger
Rage_monger Aug. 16 at 1:08 AM
$OGEN continued…
0 · Reply
NMax
NMax Aug. 15 at 11:22 PM
$OGEN if you haven't figured it out already, this is a multi-government operation. But good luck with that.
1 · Reply
RocketQueen
RocketQueen Aug. 15 at 8:58 PM
$OGEN is just a scam that's going nowhere. They still list 4 employees on their stock information. LOL At this point, it's only Janet running the bio-tech Ponzi scam with support from a criminal and greedy board. Less than a week ago, the market cap was only 2x her salary and retail thinks they can make a profit off a sinking company.
0 · Reply
RocketQueen
RocketQueen Aug. 15 at 8:45 PM
$OGEN will break 1.00 soon.
0 · Reply
hyerize
hyerize Aug. 15 at 8:15 PM
$OGEN we got a lot of characters up in here! 😆🏃🏼‍♂️🏃🏼‍♂️🏃🏼‍♂️🏃🏼‍♂️ Everyone with their 2 cents! 😆🏃🏼‍♂️🏃🏼‍♂️🏃🏼‍♂️🏃🏼‍♂️ I only complain whenever I'm losing. 💯 80% negative here. 🙄😆🏃🏼‍♂️🏃🏼‍♂️🏃🏼‍♂️ But i never try to convince anyone here to buy more or sell now 💯 Let me ride my own conclusion. I'm only here to just view other's opinions. Called Entertainment! Nothing more nothing less.
1 · Reply
Rage_monger
Rage_monger Aug. 15 at 7:51 PM
$OGEN Please feel free to pile on with me. They deserve this.
0 · Reply
Rage_monger
Rage_monger Aug. 15 at 6:51 PM
$OGEN GIRL POWER!!
0 · Reply
RocketQueen
RocketQueen Aug. 15 at 4:23 PM
$OGEN is in a precarious position, and not able to offer any reasonable gains for shareholders. It seems like company is just hanging onto corporate loopholes and market allowables.. Existential problems.
1 · Reply
RocketQueen
RocketQueen Aug. 15 at 2:29 PM
$OGEN if they added 6x shares expect another rug pull soon.
0 · Reply
Msrbutch
Msrbutch Aug. 15 at 12:22 PM
$OGEN Shorts less active: • Short interest just 1.21% of float / 0.29 days to cover – lowest in weeks. • Off-exchange short volume ratio collapsed from ~66% yesterday to ~39% today → way less hidden shorting in dark pools. • That means the constant stealth sell pressure is drying up. With shorts mostly gone and suppression tools easing, any real buying or catalyst could break this wide open. The setup is cleaner than it’s been in a long time. Anything could happen, but I’m bullish.
1 · Reply
NMax
NMax Aug. 15 at 3:45 AM
$OGEN That was a nice bit magic wasn't it?
0 · Reply
RocketQueen
RocketQueen Aug. 15 at 3:06 AM
$OGEN how did they change the numbers for the market cap?
1 · Reply
NMax
NMax Aug. 15 at 1:04 AM
$OGEN @Rocketqueen oh no sir! You are mistaken. I don't trust janet or the board. They have proven themselves crooks. And I have repeatedly said such. The thing is, I trust your intentions as much as I trust there's.
0 · Reply
mi_ama_llama
mi_ama_llama Aug. 14 at 11:39 PM
$OGEN I demand an open records to shareholders for trips to Florida and Australia...let's stop messing around and jump straight to the point
0 · Reply
mi_ama_llama
mi_ama_llama Aug. 14 at 11:30 PM
$OGEN time head to Florida and Australia to do some investigations...good write off for the company
0 · Reply